DITRAP_EU

Disarming the Immune TRAP through a Targeted Antibody Removal Therapy to Prevent ICU-Acquired Infections and Reduce Antimicrobial Resistance (DITRAP).

DITRAP is a Research and Innovation Action (RIA) funded by the European Union under Horizon Europe. The project is coordinated by REMAB Therapeutics SL (Spain) and brings together partners from Spain, Finland, the Netherlands and Belgium, to develop a novel strategy for preventing infections in intensive care units (ICUs).

Disclaimer: Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.